ALEXION PHARMACEUTICALS, INC.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public, Subsidiary
- Established
- 1992-01-01
- Employees
- 3.8K
- Market Cap
- -
- Website
- http://www.alexion.com
Expanded Access Program for Participants Who Completed Study 13-601 and Continue to Clinically Benefit From Cerdulatinib
- Conditions
- Relapsed/Refractory Chronic Lymphocytic LeukemiaNon-hodgkin's Lymphoma
- First Posted Date
- 2021-02-17
- Last Posted Date
- 2024-03-19
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Registration Number
- NCT04757259
A Study to Evaluate the Efficacy and Safety of Eculizumab in Guillain-Barré Syndrome
Phase 3
Completed
- Conditions
- Guillain-Barre Syndrome
- Interventions
- Biological: EculizumabDrug: Placebo
- First Posted Date
- 2021-02-12
- Last Posted Date
- 2024-02-09
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 57
- Registration Number
- NCT04752566
- Locations
- 🇯🇵
Clinical Trial Site, Yokohama, Japan
Ravulizumab in Thrombotic Microangiopathy Associated With a Trigger
Phase 3
Terminated
- Conditions
- Thrombotic Microangiopathy
- Interventions
- First Posted Date
- 2021-02-08
- Last Posted Date
- 2024-10-01
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 16
- Registration Number
- NCT04743804
- Locations
- 🇬🇧
Research Site, Stevenage, United Kingdom
A Study of ALXN1830 in Healthy Adult Participants
- First Posted Date
- 2021-01-29
- Last Posted Date
- 2023-01-31
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 48
- Registration Number
- NCT04730804
- Locations
- 🇳🇿
Research Site, Grafton, New Zealand
🇳🇿Clinical Trial Site, Auckland, New Zealand
A Drug Interaction Study of ACH-0145228
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2021-01-14
- Last Posted Date
- 2021-01-14
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 38
- Registration Number
- NCT04709081
- Locations
- 🇺🇸
Clinical Study Site, Tempe, Arizona, United States
A Drug Interaction Study of Danicopan
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2021-01-14
- Last Posted Date
- 2021-01-14
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 52
- Registration Number
- NCT04709094
- Locations
- 🇺🇸
Clinical Study Site, Tempe, Arizona, United States
A Study of the Cardiac Effects of ALXN2050 in Healthy Adults
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2020-12-09
- Last Posted Date
- 2021-12-29
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 39
- Registration Number
- NCT04660890
- Locations
- 🇺🇸
Clinical Trial Site, Tempe, Arizona, United States
Study of ALXN1820 in Healthy Adult Participants
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- Drug: ALXN1820 SCDrug: Placebo SCDrug: ALXN1820 IVDrug: Placebo IV
- First Posted Date
- 2020-11-17
- Last Posted Date
- 2024-08-20
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 66
- Registration Number
- NCT04631562
- Locations
- 🇬🇧
Research Site, London, United Kingdom
Study of ALXN2050 in Participants With Renal Impairment
- First Posted Date
- 2020-11-10
- Last Posted Date
- 2023-09-29
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 40
- Registration Number
- NCT04623710
- Locations
- 🇺🇸
Clinical Trial Site, Orlando, Florida, United States
A Phase 3 Study of ALXN2060 in Japanese Participants With Symptomatic ATTR-CM
Phase 3
Active, not recruiting
- Conditions
- Symptomatic Transthyretin Amyloid Cardiomyopathy
- Interventions
- First Posted Date
- 2020-11-09
- Last Posted Date
- 2024-12-16
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 25
- Registration Number
- NCT04622046
- Locations
- 🇯🇵
Research Site, Suita-shi, Japan